Pharmacokinetics/Pharmacodynamics, Efficacy and Safety of Sacubitril/Valsartan Versus Enalapril in Pediatric Patients with Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction: Study Design and Rationale
Robert E. Shaddy(University of Southern California), Michael Burch(Great Ormond Street Hospital), Fabian Chen(Brighton Hospital), Paul F. Kantor(American College of Cardiology), Damien Bonnet(World Rugby), Lazaros Kochilas(Emory Healthcare), Nancy Halnon(University of California, Los Angeles), Charles E. Canter(St. Louis Children's Hospital), Joseph Rossano, John L. Jefferies(St. Luke's Episcopal Hospital)
Cited by 0
Related Papers
2023 ESC Guidelines for the management of cardiomyopathies
|European Heart Journal|2023|2.3k
Congenital heart surgery in infants: Effects of acute kidney injury on outcomes
|Journal of Thoracic and Cardiovascular Surgery|2011|412
Changes in health in England, with analysis by English regions and areas of deprivation, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013
|The Lancet|2015|361
Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial
|The Lancet Haematology|2019|329
Prevalence, Morbidity, and Mortality of Heart Failure–Related Hospitalizations in Children in the United States: A Population-Based Study
|Journal of Cardiac Failure|2012|301